Current Status of Endoluminal Treatment of Descending Thoracic Aortic Aneurysms

A. Claire Watkins; Alex Dalal; Jason T. Lee; Michael D. Dake

doi:10.1007/s00270-020-02526-1

Current Status of Endoluminal Treatment of Descending Thoracic Aortic Aneurysms

A. Claire Watkins, Alex Dalal, Jason T. Lee, Michael D. Dake

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Thoracic endovascular aortic repair (TEVAR) was proved to be effective in thoracic descending aortic aneurysm (TDAA) repair in 1994 and approved by the FDA in 2005. Since then, TEVAR has become the first-line, recommended treatment for intact or ruptured DTAA or as a bridge to definitive open surgical repair in connective tissue disease. TEVAR has decreased perioperative morbidity and mortality compared to open surgery due to the lack of thoracotomy, aortic cross-clamping and left heart bypass. Improvement in materials, manufacturing and device delivery systems have allowed for the expansion of indications. Thoughtful and accurate pre-procedure planning is the hallmark of successful TEVAR. Familiarization and adherence to the instructions for use for an aortic device will give the best possible chance of success.

Original language	English (US)
Pages (from-to)	1770-1778
Number of pages	9
Journal	CardioVascular and Interventional Radiology
Volume	43
Issue number	12
DOIs	https://doi.org/10.1007/s00270-020-02526-1
State	Published - Dec 1 2020

Keywords

Aortic stent graft
Thoracic aortic aneurysm
Thoracic endovascular aortic repair

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Cardiology and Cardiovascular Medicine

Access to Document

10.1007/s00270-020-02526-1

Cite this

@article{2d5f36e2190b4ba89a872add1440f773,

title = "Current Status of Endoluminal Treatment of Descending Thoracic Aortic Aneurysms",

abstract = "Thoracic endovascular aortic repair (TEVAR) was proved to be effective in thoracic descending aortic aneurysm (TDAA) repair in 1994 and approved by the FDA in 2005. Since then, TEVAR has become the first-line, recommended treatment for intact or ruptured DTAA or as a bridge to definitive open surgical repair in connective tissue disease. TEVAR has decreased perioperative morbidity and mortality compared to open surgery due to the lack of thoracotomy, aortic cross-clamping and left heart bypass. Improvement in materials, manufacturing and device delivery systems have allowed for the expansion of indications. Thoughtful and accurate pre-procedure planning is the hallmark of successful TEVAR. Familiarization and adherence to the instructions for use for an aortic device will give the best possible chance of success.",

keywords = "Aortic stent graft, Thoracic aortic aneurysm, Thoracic endovascular aortic repair",

author = "Watkins, {A. Claire} and Alex Dalal and Lee, {Jason T.} and Dake, {Michael D.}",

note = "Publisher Copyright: {\textcopyright} 2020, Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).",

year = "2020",

month = dec,

day = "1",

doi = "10.1007/s00270-020-02526-1",

language = "English (US)",

volume = "43",

pages = "1770--1778",

journal = "CardioVascular and Interventional Radiology",

issn = "0174-1551",

publisher = "Springer Verlag",

number = "12",

}

TY - JOUR

T1 - Current Status of Endoluminal Treatment of Descending Thoracic Aortic Aneurysms

AU - Watkins, A. Claire

AU - Dalal, Alex

AU - Lee, Jason T.

AU - Dake, Michael D.

PY - 2020/12/1

Y1 - 2020/12/1

N2 - Thoracic endovascular aortic repair (TEVAR) was proved to be effective in thoracic descending aortic aneurysm (TDAA) repair in 1994 and approved by the FDA in 2005. Since then, TEVAR has become the first-line, recommended treatment for intact or ruptured DTAA or as a bridge to definitive open surgical repair in connective tissue disease. TEVAR has decreased perioperative morbidity and mortality compared to open surgery due to the lack of thoracotomy, aortic cross-clamping and left heart bypass. Improvement in materials, manufacturing and device delivery systems have allowed for the expansion of indications. Thoughtful and accurate pre-procedure planning is the hallmark of successful TEVAR. Familiarization and adherence to the instructions for use for an aortic device will give the best possible chance of success.

AB - Thoracic endovascular aortic repair (TEVAR) was proved to be effective in thoracic descending aortic aneurysm (TDAA) repair in 1994 and approved by the FDA in 2005. Since then, TEVAR has become the first-line, recommended treatment for intact or ruptured DTAA or as a bridge to definitive open surgical repair in connective tissue disease. TEVAR has decreased perioperative morbidity and mortality compared to open surgery due to the lack of thoracotomy, aortic cross-clamping and left heart bypass. Improvement in materials, manufacturing and device delivery systems have allowed for the expansion of indications. Thoughtful and accurate pre-procedure planning is the hallmark of successful TEVAR. Familiarization and adherence to the instructions for use for an aortic device will give the best possible chance of success.

KW - Aortic stent graft

KW - Thoracic aortic aneurysm

KW - Thoracic endovascular aortic repair

UR - http://www.scopus.com/inward/record.url?scp=85085307959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085307959&partnerID=8YFLogxK

U2 - 10.1007/s00270-020-02526-1

DO - 10.1007/s00270-020-02526-1

M3 - Review article

C2 - 32449019

AN - SCOPUS:85085307959

SN - 0174-1551

VL - 43

SP - 1770

EP - 1778

JO - CardioVascular and Interventional Radiology

JF - CardioVascular and Interventional Radiology

IS - 12

ER -

Current Status of Endoluminal Treatment of Descending Thoracic Aortic Aneurysms

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this